Visus Therapeutics announced today that three novel presbyopia treatments achieved their improvement endpoints in a Phase 2 study. Seattle-based Visus' Vivid Phase 2 study observed all three of the included investigational candidates achieve the … [Read More...] about Visus Therapeutics touts data from trial of presbyopia treatment
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
Tandem Diabetes Care expands leadership team
Automated insulin delivery technology developer Tandem Diabetes Care (NSDQ:TNDM) announced new appointments in three executive leadership positions. San Diego-based Tandem named Rick Carpenter as CTO, Libba Sapitsky as SVP of Customer Care and … [Read More...] about Tandem Diabetes Care expands leadership team
FDA grants breakthrough nod to Zetagen’s metastatic bone cancer treatment
Zetagen Therapeutics announced today that it received FDA breakthrough device designation for its ZetaMet cancer treatment technology. Syracuse, New York-based Zetagen designed its ZetaMet (previously known as ZetaFuse) as a synthetic, … [Read More...] about FDA grants breakthrough nod to Zetagen’s metastatic bone cancer treatment
Bigfoot Biomedical touts cloud-based program for managing diabetes
Bigfoot Biomedical officials think their Bigfoot Unity diabetes management program and Bigfoot Clinic Hub could up the game in the space. Milpitas, California-based Bigfoot designed the Bigfoot Unity platform to allow healthcare professionals … [Read More...] about Bigfoot Biomedical touts cloud-based program for managing diabetes
Visus Therapeutics touts data from trial of presbyopia treatment
Visus Therapeutics announced today that three novel presbyopia treatments achieved their improvement endpoints in a Phase 2 study. Seattle-based Visus' Vivid Phase 2 study observed all three of the included investigational candidates achieve the … [Read More...] about Visus Therapeutics touts data from trial of presbyopia treatment
FDA authorizes expansion of Fractyl’s pivotal clinical trial for diabetes reversal tech
Fractyl Health announced today that the FDA gave authorization to expand the Revitalize-1 pivotal clinical study of its Revita DMR system. Lexington, Massachusetts-based Fractyl Health (formerly Fractyl Laboratories) can now increase the sample … [Read More...] about FDA authorizes expansion of Fractyl’s pivotal clinical trial for diabetes reversal tech
AMF Medical wins breakthrough nod for insulin management system
AMF Medical announced today that it received FDA breakthrough device designation for its Sigi insulin management system. Ecublens, Switzerland-based AMF Medical's Sigi (for diabetes mellitus treatment) can be programmed to deliver basal and bolus … [Read More...] about AMF Medical wins breakthrough nod for insulin management system
Medtronic plans to bring next-gen diabetes tech to FDA this fiscal year, no spinoff planned
Medtronic (NYSE:MDT) confirmed that it anticipates major regulatory steps for its next-generation insulin pump and sensor during this fiscal year. Medtronic's fiscal years wrap up at the end of April. Speaking on the company’s second-quarter … [Read More...] about Medtronic plans to bring next-gen diabetes tech to FDA this fiscal year, no spinoff planned
BioMarin wins FDA approval for injection to increase growth in children with dwarfism
BioMarin Pharmaceutical (NSDQ:BMRN) announced today that the FDA granted accelerated approval for its Voxzogo injection. San Rafael, California-based BioMarin's Voxzogo (vosoritide) injection has an indication to increase linear growth in … [Read More...] about BioMarin wins FDA approval for injection to increase growth in children with dwarfism
ICU Medical’s Smiths Medical acquisition remains on track
ICU Medical (NASDAQ:ICUI) is a step closer to acquiring Smiths Medical after clearing a shareholders vote at Smiths' British parent company, the Smiths Group. Almost all of the nearly 327 million Smiths Group shareholders voting on November 17 … [Read More...] about ICU Medical’s Smiths Medical acquisition remains on track
Better Therapeutics completes enrollment in type 2 diabetes study
Better Therapeutics (NSDQ:BTTX) announced that it completed patient enrollment in a study of its digital therapeutic in treating diabetes. San Francisco-based Better Therapeutics' BT-001 prescription digital therapeutic delivers a novel … [Read More...] about Better Therapeutics completes enrollment in type 2 diabetes study
In case you missed it
- FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump
- Diabeloop, Terumo partner to bring automated insulin delivery to Europe
- How some diabetes tech companies are honoring National Diabetes Month
- FreeStyle Libre 3, other Abbott products recognized at CES Innovation Awards
- Stevanato Group expands corporate headquarters
- Cure Pharmaceutical wins patent approval for fast-dissolving drug delivery platform
- BD breaks ground on pre-filled syringe manufacturing plant in Spain
- 7 diabetes treatment innovations to look out for on World Diabetes Day
- Omnicell, Fresenius Kabi collaborate on controlled substance dispensers
- Senseonics posts Q3 earnings beat, hopes for new FDA approval soon
- Stevanato Group beats The Street in Q3, raises guidance
- World faces a shortage of up to 2 billion COVID-19 vaccine syringes
- Ocular Therapeutix claims win as court invalidates drug delivery patent from Mati
- Abbott, American Diabetes Association partner to help people of color with diabetes
- Gyroscope Therapeutics to receive investment from Sanofi worth up to $60M
Clinical Trials
Visus Therapeutics touts data from trial of presbyopia treatment
Visus Therapeutics announced today that three novel presbyopia treatments achieved their improvement endpoints in a Phase 2 study. Seattle-based Visus’ Vivid Phase 2 study observed all three of the included investigational candidates achieve the endpoint of three lines of improvement in binocular near visual activity without losing one line of distance vision with a minimum […]
FDA authorizes expansion of Fractyl’s pivotal clinical trial for diabetes reversal tech
Fractyl Health announced today that the FDA gave authorization to expand the Revitalize-1 pivotal clinical study of its Revita DMR system. Lexington, Massachusetts-based Fractyl Health (formerly Fractyl Laboratories) can now increase the sample size of the Revitalize-1 trial (formerly Revita-T2Di trial) from 288 to 420. In September, Fractyl activated the 10th clinical site in the […]
Medtronic plans to bring next-gen diabetes tech to FDA this fiscal year, no spinoff planned
Medtronic (NYSE:MDT) confirmed that it anticipates major regulatory steps for its next-generation insulin pump and sensor during this fiscal year. Medtronic’s fiscal years wrap up at the end of April. Speaking on the company’s second-quarter earnings call, Chair & CEO Geoff Martha said Medtronic expects its MiniMed 780G insulin pump system with the Guardian 4 […]
Better Therapeutics completes enrollment in type 2 diabetes study
Better Therapeutics (NSDQ:BTTX) announced that it completed patient enrollment in a study of its digital therapeutic in treating diabetes. San Francisco-based Better Therapeutics’ BT-001 prescription digital therapeutic delivers a novel cognitive-behavioral therapy to patients with uncontrolled type 2 diabetes. According to a news release, the trial for BT-001 exceeded its enrollment target, bringing in 662 […]
7 diabetes treatment innovations to look out for on World Diabetes Day
World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes. This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease. Some of those treatments involve insulin, which was discovered as a treatment for diabetes in […]
